PAINCHEK LTD — AGM Information 2021

Nov 29, 2021

==> picture [320 x 93] intentionally omitted <==

==> picture [463 x 145] intentionally omitted <==

AGM Investor Update November 30 2021

PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK

==> picture [320 x 93] intentionally omitted <==

CORPORA TE OVERVIEW

==> picture [54 x 55] intentionally omitted <==

• PainChek provides Software-As-A-Service that uses AI for the detection of patient pain via video analysis

• Targeting enterprise customers who have patients with an inability to communicate pain levels (e.g. dementia)

• Technology is clinically & commercially validated, has key regulatory approvals & is unique

==> picture [54 x 55] intentionally omitted <==

• Multiple peer reviewed publications & clinical trials – 90% + concordance to existing methods

• Adult and Infant Apps regulatory cleared for sale in Australia, Europe, UK, NZ, Singapore & Canada, FDA in progress

• • Patent granted in US, Japan, Australia and China – awaiting grants in Europe – protection until 2037

• Large global markets - now in global commercialization phase based on strong Australia take up

==> picture [54 x 55] intentionally omitted <==

• Over 1,500 aged care facilities & 126,000 beds already signed up to SaaS contracts in Australia – 60% market share

• • UK sales accelerating with NZ and Singapore underway

• 80-85% long term gross margins & recurring revenue each month

• Multiple new products scheduled for launch over next 2 years to drive further growth (B2C dementia, infant/toddler)

==> picture [55 x 55] intentionally omitted <==

• Better outcomes for patients & enterprise customers

• Improved patient care – more targeted treatments & better outcomes

• Improves efficiency – saves customers money – less data entry/labour, less adverse patient events

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

2 |
----- End of picture text -----

Our purpose is to give a voice to people who cannot reliably verbalise their pain

==> picture [236 x 316] intentionally omitted <==

==> picture [172 x 299] intentionally omitted <==

==> picture [172 x 299] intentionally omitted <==

==> picture [236 x 316] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

3 |
----- End of picture text -----

THE INITIAL SIZE OF THE PROB LEM

==> picture [313 x 169] intentionally omitted <==

400M pre-verbal children

==> picture [318 x 167] intentionally omitted <==

50M people living with dementia

==> picture [320 x 93] intentionally omitted <==

25-42%

of hospital beds occupied by people with dementia

==> picture [316 x 167] intentionally omitted <==

1. Ecology Communications Group. www.ecology.com/birth-death-rates

2. World Alzheimer Report 2016

3. Germossa et al. BMC Nursing (2019) 18:40

4. Tsai, I. P., Jeong, S. Y. S., & Hunter, S. (2018). Pain assessment and management for older patients with dementia in hospitals: an integrative literature review. Pain Management Nursing , 19 (1), 54-71.

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

4 |
----- End of picture text -----

W HERE PAINCHEK STARTED

==> picture [320 x 93] intentionally omitted <==

Australian Residential Aged Care

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

5 |
----- End of picture text -----

PAINCHEK UNIVERSA L SOLUTI ON NOW CE & TGA CLEARED

==> picture [217 x 406] intentionally omitted <==

==> picture [68 x 68] intentionally omitted <==

==> picture [68 x 68] intentionally omitted <==

==> picture [68 x 69] intentionally omitted <==

Accelerates adoption by new clients and supports retention of existing clients

Broadens PainChek global market opportunity in aged care, home care and hospitals segments

Provides greater insights for medical decision making on pain management & new product development and collaborative opportunities with therapeutics industry

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

6 |
----- End of picture text -----

PAINCHEK’ S SUCCESSFU L DEVELOPME N T

==> picture [320 x 93] intentionally omitted <==

According to University of Successfully establishing PainChek is on the cusp Cambridge research, it takes up to the technology, by of achieving commercial ten years for the development commercialising it in more than success in multiple of a medical device one market, takes even longer markets after just five years

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

7 |
----- End of picture text -----

201 7 – INITIAL STEPS OF DEVELOPME N T

4. Covered in 3. several clinical Regulatory publications 2. clearances in AU/EU (CE/TGA) First version of 1. Commercial Listed on the App Adult ASX in Q4 2016

==> picture [320 x 93] intentionally omitted <==

6. 1st RAC sale & 5. integration Global, perpetual agreement – AI license 50 beds, $2.5K ARR agreement

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

8 |
----- End of picture text -----

T o 1 5 0 0 R A C ’ s , 1 2 0 , 0 0 0 +b e d s , a c r o s s 4 c o un tr i e s a n d A R R o f $5 . 5 M*

==> picture [939 x 394] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

9 |
----- End of picture text -----

I N T E G R A T I O N P A R T N E R S – F r o m o n e i n t e g r a t i o n p a r t n e r i n 2 0 1 8 t o 1 1 i n A u s t r a l i a , 4 i n U K , 4 i n N Z a n d 1 i n C a n a d a

PainChek is integrated with aged care management systems covering more than 180,000 aged care beds in Australia, 25,000 beds in New Zealand, and 140,000 beds in the UK.

Point of care PainChek assessments on a resident is automatically transmitted to the care management system in the aged care centre driving better care and reducing duplication of data entry.

==> picture [754 x 282] intentionally omitted <==

----- Start of picture text -----

UNITED KINGDOM
A U S T R A L I A
NEW ZEALAND
----- End of picture text -----

==> picture [139 x 139] intentionally omitted <==

----- Start of picture text -----

CANADA
----- End of picture text -----

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

10 |
----- End of picture text -----

PAINCHEK ®’ S GROW ING PRESENCE IN RAC’S ACROSS AUSTRA LI A

==> picture [960 x 418] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

11 |
----- End of picture text -----

P R O J E C T E D A R R * C O V E R S C O R E P C K A UST R A L I A N BUSI N E S S C O ST S

==> picture [401 x 296] intentionally omitted <==

==> picture [10 x 314] intentionally omitted <==

PainChek market

penetration of 128,504 beds — projecting $5.67m ARR — post govt trial

• Provides a validated platform for global expansion

• Projected ARR would result in PCK covering the current Australian operational cost base

• Outstanding opportunity for a highly profitable global business in aged care, with significant upside from home care & hospital settings and large children’s market

• Normalised ARR is post completion of the government grant reflecting contracted or standard pricing on completion of the trial. It assumes all clients implement the PainChek App and enter a standard PainChek contract after the initial 12-month grant period. So far clients representing 75% of contracted beds have entered into agreements that have second year commercial terms post completion of the government grant period.

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

12 |
----- End of picture text -----

PAINCHEK ® PROVEN PRODUCT AND B USINESS MODEL

• 1,559 Aged Care facilities contracted across four continents – up 96% year on year

128,504 beds under contract in Aged Care – up 92% year on year

==> picture [418 x 304] intentionally omitted <==

==> picture [418 x 304] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

Figures based on September 2021 ASX releases 13
----- End of picture text -----

T R A N SI T I O N I N G G O V T FUN DE D BE DS T O ST A N DA R D P C K L I C E N SE S

RAC beds by commercial, active and yet to go live

RAC beds by commercial, active and yet to go live

==> picture [856 x 304] intentionally omitted <==

----- Start of picture text -----

NUMBER OF BEDS ARR $M
$6.00
140,000
120,000 $5.00
100,000 $3.05
74,758 $4.00 $3.30
82,346
80,000
$3.00
60,000 $2.03
48,599
$2.00
40,000 $1.80
36,620 $1.60
32,349
$1.00
20,000 26,082 $1.24
14,494 17,069 $0.67 $0.82
- 5,356 $- $0.21
MA R - 21 J U N - 21 S E P - 21 MA R - 21 J U N - 21 S E P - 21
Beds paying commercial fees - number Beds active & extensions - number
Beds to be implemented - number Beds paying commercial fees - ARR Beds active & extensions - ARR
Beds to be implemented - ARR
----- End of picture text -----

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

14 |
----- End of picture text -----

T R A N SI T I O N I N G L A R G E C L I E N T – P R E a n d P O ST G O V T G R A N T

==> picture [832 x 330] intentionally omitted <==

----- Start of picture text -----

3500 $180,000
$160,000
3000
$140,000
2. Grant Funded Year
2500 1. Pilot and initial rollout 3. Rollout post grant, full commercial rate
$76K one off payment
$120,000
2000
$100,000
$80,000
1500
$60,000
1000
$40,000
500
$20,000
0 $0
Dec-18 Jun-19 Dec-19 Mar-20 Mar-21 Jun-21 Sep-21 Oct-21 Dec-21
Beds implemented Beds contracted Actual ARR ($) Grant ARR ($)
----- End of picture text -----

1. PainChek signed 3,300 beds across 45 RACs @ $50/bed/annum in 2018.

2. In Qtr 1 2020 client switched to 2,000 Government funded dementia beds, government pays PCK @$38 per dementia bed.

3. By Qtr 2 2021 client reverted to PCK contract terms, paying PCK $50/bed (or MRR $13,750/month when fully rolled out)

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

15 |
----- End of picture text -----

KPMG CONDUCT S FIRST PHASE EVALUATI O N OF PAINCHEK AS PART OF THE RESID ENT IA L A GED CARE NATIONA L TRIAL

CLIENT QUOTES FROM THE FIRST PHASE REPORT

EVALUATION PROGRAM

“ “Practical Practical education was very useful. We made sure we all had tablets, so we haven’t come up against barriers. It’s been painless for us.” - Manager

• KPMG were engaged to conduct a 3[rd] party evaluation of the PainChek for Aged Care providers for future Federal Government policy making

• The first phase of the program evaluated the effectiveness of PainChek implementations including onboarding, training and support.

• The next phase of the program will evaluate the clinical and economic impacts of PainChek, throughout 2022.

“We get a report from PainChek. I go into the assessments and I can see who is using it, who is not using it and who is still using the Abbey. I can identify who has it by looking who was on shift. I review the documents daily to see what has come up and can keep a track on it - Manager

“Our relationship with [the Clinical Consultant] was integral. She was so easy and responsive, you could email her any time and she would organise something for us” – Manager

“I think it’s a fantastic idea” – Family member

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

16 |
----- End of picture text -----

PAINCHEK - B UILD ING A GLOB AL DIGITAL CAPAB ILIT Y

==> picture [839 x 395] intentionally omitted <==

----- Start of picture text -----

Engage Implement Clinical Support &
Sell Train Utility Insights
• Worldwide App Downloads
Digital marketing lead
16000
generation
14000
•
Teams and Zoom based
12000
sales presentations
10000
• Video and web chat 8000
6000
•
Cloud based Contract
4000
management and CRM
2000
•
Content rich website
0
Apple Google Total
----- End of picture text -----

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

17 I
----- End of picture text -----

PAINCHEK - B UILD ING A GLOB AL DIGITAL CAPAB ILIT Y

==> picture [835 x 114] intentionally omitted <==

----- Start of picture text -----

Engage Implement Clinical Support &
Sell Train Utility Insights
----- End of picture text -----

• eLearning platform and certification

• Training videos

• Online workshop training 1:1 and classroom

• App Store downloads (Apple & Google)

• Security protected

• Online integration

==> picture [448 x 248] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

18 I
----- End of picture text -----

PAINCHEK – B UILD ING A GLOB AL DIGITAL CAPAB ILI TY

==> picture [835 x 114] intentionally omitted <==

----- Start of picture text -----

Engage Implement Clinical Support &
Sell Train Utility Insights
----- End of picture text -----

• Integration with customer medical records

• Secure digital storage and privacy of data

• Secure user access

• Detailed usage reporting

• Data reports help care homes meet accreditation standards

==> picture [385 x 238] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

19 I
----- End of picture text -----

PAINCHEK – B UILD ING A GLOB AL DIGITAL CAPAB ILI TY

==> picture [835 x 131] intentionally omitted <==

----- Start of picture text -----

Engage Implement Clinical Support &
Sell Train Utility Insights
Given a patient in pain was reassessed within 24 hours, what was their resulting pain level?
----- End of picture text -----

• Single support line number

• Online help library and guides

• Continuous maintenance through cloud updates

• PCK Portal to assess data and provide insights

==> picture [113 x 255] intentionally omitted <==

==> picture [113 x 255] intentionally omitted <==

==> picture [113 x 255] intentionally omitted <==

==> picture [113 x 255] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

20 I
----- End of picture text -----

NEW MARKET EXPANSIO N – AUSTRA LI A

==> picture [320 x 93] intentionally omitted <==

Home Care

• 1[st] reseller & integration partnership with Medication Management provider

• world first end-to-end medication management solution with integrated pain management

• PCK direct sales to Home Care providers commenced

Hospitals

• Ramsay Hospitals research program - Hollywood Hospital

• Joondalup hospital

• 1[st] collaborative clinical publication – Edith Cowan University

==> picture [158 x 158] intentionally omitted <==

----- Start of picture text -----

New markets
Green shoots
----- End of picture text -----

Disability

• Nulsen disability trial complete

• • Trial outcomes to be

• disseminated and shared with other NDIS providers

• • Expand reach to other NDIS groups from Q4 2021

Business Development

• PainChek brand awareness driving new opportunities

• Technology

• Distribution

• Partnerships

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

21 |
----- End of picture text -----

AUSTRA L IA N HOME CARE MARKET OPPORTU NI T Y

==> picture [662 x 406] intentionally omitted <==

----- Start of picture text -----

Home Care
providers (535)
60% of market
Partnerships
RAC operators
with home
care package
PainChek initial
PainChek
targeting
existing RAC
clients
Direct Sales 40% of market
Private Home
Care package
providers
Targeting those with
dementia care focus
----- End of picture text -----

MARKET OPPORTUNITY

• PainChek estimates there is 235,500 Home Care consumer packages in Australia

• The top 25 home care providers control 44% of home care packages & PainChek has existing license agreements with 13 of those

• This creates an estimated $5-10m pa. local market opportunity

• ~$100m-$200m pa. global market opportunity

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

22 |
----- End of picture text -----

DISABILITY MARKET OPPORTUNITY UPDATE

NULSEN TRIAL DELIVERS POSITIVE OUTCOMES

CURTIN UNIVERSITY STUDY SUPPORTS PAINCHEK’S POTENTIAL IN THE SECTOR

• PainChek detected previous undiagnosed pain

• Supports NDIS requirements around safeguarding resident / clients • Improves quality of life and social engagement • Consistent identification and documentation of pain • Residents with pain at comparable level (36.7% vs 48.9%) to aged care where PainChek has experienced great success

• Positive resident / client outcomes

• New insights into pain

• prevalence and associations for those with a disability

==> picture [320 x 93] intentionally omitted <==

INDUSTRY PRIMED FOR PAINCHEK’S ENTRY

• PainChek increasing engagement in disability support industry in CY2022

• Continuing to work with

• Nulsen to benefit from its learnings

• Exploring additional

• partnership opportunities to accelerate rollout

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

23 |
----- End of picture text -----

PROGRESS IN OTHER REGULA TO R Y CLEARED MARKETS

US / FDA • Presubmission for de novo scheduled for Q4 CY21 • Clinical study to commence Q1 CY22 • Clearance submission Q2/Q3 CY22 Canada– new client & integration partner opportunities Regulatory submission & clearance in process Countries with regulatory clearance	US / FDA • Presubmission for de novo scheduled for Q4 CY21 • Clinical study to commence Q1 CY22 • Clearance submission Q2/Q3 CY22 Canada– new client & integration partner opportunities Regulatory submission & clearance in process Countries with regulatory clearance																									NZ • Summerset & Presbyterian Support – both pilots contracted & live • Expansion to additional sites scheduled on pilot completion • VCARE & MediMap integrations
	– new client ti t	&												Ireland–					–							• • •
	/ FDA * bmission for de on parner ortunities									UK • ~3,000 beds signed up • 1,600 beds live
	cheduled for 21 al study to ence Q1 CY22 nce submission CY22									• Strong sales pipeline								Singapore
																		new client & integration partner opportunities

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

24 |
----- End of picture text -----

==> picture [320 x 93] intentionally omitted <==

PAINCHEK UK PROGRESS GAINING MOMENT U M

“

The teams that are using PainChek absolutely love it. It has given them a real insight into a persons needs and we are getting some fantastic outcomes for residents and staff! ”

==> picture [73 x 73] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

==> picture [37 x 38] intentionally omitted <==

UK market traction growing – ~3,000 beds signed up, 1,600 live & strong pipeline for Q4 CY21

PainChek to be featured in Care South Group dementia strategy across 1,300 beds

Rollout completed with Erskine Hospitals (Scotland), Orchard Care (1,100 beds) & Handsale (550 beds)

“

…we’re getting some fantastic outcomes for residents and for staff…they can really make a difference now, quite quickly…

”

==> picture [45 x 45] intentionally omitted <==

==> picture [44 x 44] intentionally omitted <==

==> picture [51 x 45] intentionally omitted <==

“

It has improved their nutrition… mental health… & physical health, simply by addressing one area of their concerns we have a positive impact on the rest of their health and wellbeing; so it has been magnificent.

Excellent feedback being received from early UK adopters

Team expanded to accelerate new business development

Focus on delivering CMS partner integrations – three set to occur by 31 Dec

”

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

25 |
----- End of picture text -----

INFANT APP REGULATORY CLEARED FOR SALE IN MULTIPLE MARKETS*

Global market opportunity very large with low customer acquisition cost

World first facial recognition technology to assess pre-verbal infant procedural pain through a 3 second AI based video analysis of the face – CE & TGA clearance for Infant version achieved Q2 CY21

PCK infant clinical study published in Lancet Digital Health August 2021

APP SCREENSHOT

==> picture [206 x 201] intentionally omitted <==

CONSUMER PRE-VERBAL CHILDREN MARKET VALUE Indicative App Price A$10/month Net Revenue after app store A$7/month commissions No. 0-3 year old Worldwide 400m No of Infants (1 month to 1 year) 140m MARKET SHARE EXAMPLES

400k subscribers = 0.1% Global Market Share A$33.6m Annualised Revenue 4m subscribers = 1% Global Market Share A$336m Annualised Revenue

TARGET MARKETS

Children’s Hospitals Post surgical units Health care professionals General Practitioners Parents Day care workers

1 http://www.ecology.com/birth-death-rates

2 ABS 2016 3 Management Estimates

• Regulatory clearances received in Australia, UK, Europe, Canada, Singapore and New Zealand

==> picture [320 x 93] intentionally omitted <==

PAINCHEK INFANT INITIAL TARGET MARKET S

==> picture [63 x 44] intentionally omitted <==

1. Post vaccination

Approx. 140 million children born globally each year including 300,000 in Australia – 95% fully immunised at 12 months after five immunization appointments

==> picture [41 x 55] intentionally omitted <==

2. Post operative

Pain associated with surgical procedures (e.g. post tonsillectomy), & where parents are required to deliver pain management in the home

==> picture [69 x 43] intentionally omitted <==

3. Partnerships & licensing

Targeting global therapeutic companies providing pain medication and management for health care professional and families

PainChek Infant is intended for use to assess procedural pain associated with medical investigations or treatments e.g. immunisations, suturing & dressing changes, invasive procedures such as fracture reductions or bone marrow biopsies

Users of PainChek Infant can include healthcare professionals or laypersons, in settings including hospitals, day surgery centres, GP clinics or the home

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

27 |
----- End of picture text -----

PAINCHEK’ S POTENTIA L AS A KEY TOOL IN INFANT COVID-1 9 VACCINATI O N S

THE CHALLENGE

THE OPPORTUNITY

VACCINATION FOR YOUNGER AGE GROUPS REDUCTION IN PARENTAL RISK AVERSION COVID-19 vaccination Likely to create numerous programme expected to shift adverse effects that can to younger age groups cause parental vaccine including 6-12 month infants hesitancy

==> picture [178 x 177] intentionally omitted <==

EXISTING IMMUNISATION PROGRAMME COVID-19 vaccine would be administered as the sixth vaccination within the existing immunisation programme for children

FILL A GAP IN THE PROGRAMME Given infants are unable to self-report their pain, PainChek Infant can fill a gap in the vaccination programme , managing post-vaccination pain and reducing parental distress and potential vaccine hesitancy

==> picture [42 x 42] intentionally omitted <==

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

28 |
----- End of picture text -----

HOW PAINCHEK ® INFANT CAN SUPPOR T HCP’s AND PARENTS B ETTER MANAGE POST VACCINAT IO N PAIN FOR INFANTS

1. Infant receives the vaccine, most often resulting in acute, short-lived pain

BENEFITS

• Simple, cost-effective & can be implemented now

2. PainChek Infant made available to immuniser to document pain resolution pre-discharge from the clinic

3. pain and how to assess it using PainChek® Infant at homeParent is educated on signs/symptoms of post-immunisation

• Actively supports monitoring of vaccination safety leading to enhanced parental confidence

• Generates real time medication safety data for Government bodies/agencies

If pain persists, parent has been educated in terms 4. of next course of action

• Potential reduction in hospital and doctor office visits post-vaccination

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

29 |
----- End of picture text -----

THE TEAM

==> picture [100 x 100] intentionally omitted <==

Philip Daffas CEO & Managing Director, MBA, BSc

==> picture [100 x 100] intentionally omitted <==

Prof. Jeff Hughes Chief Scientific Officer PhD, MPS

==> picture [100 x 100] intentionally omitted <==

==> picture [320 x 93] intentionally omitted <==

==> picture [99 x 102] intentionally omitted <==

Iain McAdam CFO

Andrew Hoggan Head of Operations

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia.

Jeff is a professor in the School of Pharmacy, Curtin University in Western Australia. Jeff is one of the team who developed the PainChek® concept.

Andy is a Psychologist, management consultant, business leader & executive coach. Andrew has worked in both Australia & the UK across aged care & home care services.

Iain has over 20 years finance & transformational change experience within listed high growth multinational software & services companies, including iSoft & eServGlobal.

==> picture [100 x 103] intentionally omitted <==

Scott Robertson Chief Technology Officer, MBA, B.Eng.(Comp. Systems)

==> picture [98 x 103] intentionally omitted <==

David Allsopp Head of Business Development ANZ

==> picture [95 x 103] intentionally omitted <==

Tandeep Gill Senior Business Development Manager, UK

Scott has over 25 years’ experience designing, deploying & managing enterprise software systems, adapting to changing client needs.

David has extensive account management, relationship management. He is renowned for establishing trusting, transparent & long-standing relationships in the healthcare space.

Tandeep is a registered pharmacist in both the hospital & community setting, with ten years experience in senior health & social care positions. He has spent three years leading the advancement of technology solutions in the UK.

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

30 |
----- End of picture text -----

THE BOARD

==> picture [320 x 93] intentionally omitted <==

==> picture [166 x 167] intentionally omitted <==

----- Start of picture text -----

John Murray
Chairman
----- End of picture text -----

==> picture [165 x 166] intentionally omitted <==

==> picture [166 x 169] intentionally omitted <==

==> picture [166 x 168] intentionally omitted <==

John Murray Non-Exec Chair

Philip Daffas

CEO & Managing Director

Ross Harricks

Non-Exec Director

Adam Davey Non-Exec Director

25 years in tech & Venture Capital. Founder of Technology Venture Partners, ex Chair of Residential Aged Care provider. Multiple non-exec board roles.

Philip is a highly accomplished global business leader & people manager. Philip has held senior global leadership positions with Cochlear & Roche in Europe, US & Australia.

Senior global medical device executive with Nucleus & experienced healthcare NED.

Corporate finance executive with extensive capital markets experience.

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

31 |
----- End of picture text -----

CORPORATE SUMMARY

==> picture [320 x 93] intentionally omitted <==

	Share price (29 November 2021) A$0.065 Shares on issue 1,132.6m Market capitalisation A$73.6m Cash (30 September 2021) A$9.7m Unlisted options/performance rights 58.8m Debt Nil Financial information Top shareholders % Peters Investments Proprietary Ltd 9.98% Board & key staff 4.3%

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

32 |
----- End of picture text -----

==> picture [320 x 93] intentionally omitted <==

PAINCHEK STRATEGIC PILLARS FOR FY’22

STRATEGIC NEW PRODUCT & GLOBAL MARKET ENTRIES

CORE RAC MARKET EXPANSION

BROADEN ADULT APP MARKETS

• Implement balance of 120,000 contracted beds in Australia and transition to standard PCK contracts – targeting $5.5m ARR

• • Expansion of UK beds licences & integrations

  • Commercialise the Infant App - post vaccination initial focus - HCP’s and home consumers - global therapeutic partnerships

  • • Submit FDA de novo clinical study

  • • Establish market entry model & partnerships for EU & Asia

• Build Home Care & Hospital business model & sales in ANZ

• • Establish disability market entry model

• • Leverage ANZ learnings into UK & other overseas markets as fast followers

• Establish broader market position in NZ, Singapore & Canada

==> picture [960 x 37] intentionally omitted <==

----- Start of picture text -----

33 |
----- End of picture text -----

Within five years PainChek has successfully commercialised its technology…. and is now on the cusp of establishing it within multiple new markets and on an international basis Q&A

PHILIP DAFFAS, CEO & MD

PAINCHEK LTD | ASX:PCK